SanBio: [Delayed] The latest information regarding the report on ACUUGO suspension fluid for intracranial transplantation can be found here.
SanBio: Report on 'ACUUGO Suspension for Cranial Transplantation' which was delayed.
SanBio: Regarding the partial report on Accugo's intracranial transplantation injection (follow-up report).
SanBio: Regarding some reports on "Acuugo brain transplantation injection"
SanBio: Further updated information regarding the manufacturing and sales approval status of the SB623 chronic traumatic brain injury (TBI) program in Japan.
SanBio: Update on the status of the approval for manufacturing and selling the domestic SB623 chronic traumatic brain injury program.
SanBio: Announcements of individual stocks regarding the recording of non-operating income and adjustments for corporate taxes.
SanBio: Consolidated financial results for the three months ended April 30, 2024 [Japanese Accounting Standards]
SanBio: Announcements of individual stocks regarding recognition of non-operating income and deferred income taxes.
SanBio: Further updated information regarding the manufacturing and sales approval status of the SB623 chronic traumatic brain injury (TBI) program in Japan.
SanBio: Status update on the manufacturing approval for the domestic SB623 chronic traumatic brain injury program (continuation report).
SanBio: Matters relating to business plans and growth potential
SanBio: [Delayed] Further Update on Status of Manufacturing and Marketing Approval for SB623 Chronic Traumatic
SanBio: Status of obtaining manufacturing and sales approval for the domestic SB623 chronic traumatic brain injury program (follow-up report)
SanBio: Presentation for Financial Results for the Fiscal Year Ending Jan.31, 2024
SanBio: Consolidated Financial Results for the Fiscal Year Ended January 31, 2024 [Japanese GAAP]
SanBio: Notice Concerning Recording of Non-operating Income, Extraordinary Gains, and Deferred Income Taxes
SanBio: Announcement on Reduction in Amounts of Stated Capital and Capital Reserves and Appropriation of Other Capital Surplus
SanBio: Notice Concerning Differences between Consolidated Earnings Forecast and Actual Results for the Fiscal Year Ending January 31, 2024
SanBio: Notice regarding a decrease in the amount of capital and capital reserves and the disposal of other capital surpluses
No Data